PMID- 36753186
OWN - NLM
STAT- MEDLINE
DCOM- 20230210
LR  - 20230328
IS  - 2164-2591 (Electronic)
IS  - 2164-2591 (Linking)
VI  - 12
IP  - 2
DP  - 2023 Feb 1
TI  - Inner Retinal Changes in Acute Experimental BRVO Treated With Bevacizumab or 
      Triamcinolone Acetonide.
PG  - 11
LID - 10.1167/tvst.12.2.11 [doi]
LID - 11
AB  - PURPOSE: Apoptosis is a key process in neural degeneration associated with 
      retinal vascular diseases. Vascular endothelial growth factor (VEGF) antagonists, 
      including bevacizumab, are used to treat macular edema in these diseases. As VEGF 
      has a critical role in the preservation of retinal neuronal cells, this study 
      investigates the effects of bevacizumab on neural damage in a pig model of branch 
      retinal vein occlusion (BRVO) and compares it with triamcinolone acetonide (TA) 
      which is reported to possess neuroprotective properties. METHODS: Thirty-six pigs 
      had a photothrombotic BRVO in both eyes. Six pigs were injected with bevacizumab 
      in one eye and TA in the fellow eye, then they were sacrificed, the eyes 
      enucleated, and retinas processed at 2, 6, 10, and 20 days, respectively, 
      together with three pigs (six eyes) BRVO only and three normal pigs (six eyes). 
      Neuronal degeneration (apoptosis) and associated inner retinal changes were 
      determined by terminal deoxyynuclotidyl transferase dUTP nick-end labeling 
      (TUNEL), histology, and immunohistochemistry for macrophages. RESULTS: TUNEL 
      labeling showed significantly higher apoptosis rates in the ganglion cell layer 
      (GCL) and the inner nuclear layer (INL) in the bevacizumab-treated compared with 
      the TA-treated retinas at 2, 10, and 20 day time points after occlusion (P < 
      0.05). Pyknotic cells were significantly higher in the GCL in bevacizumab-treated 
      eyes at 6, 10, and 20 days and in the INL at 2 days compared to TA-treated 
      retinas (P < 0.05). Macrophage infiltration was seen at all time points in both 
      untreated and treated retinas with an absence of significance between 
      bevacizumab- and TA-treated retinas (P > 0.05). CONCLUSIONS: Neurodegeneration in 
      the BRVO acute phase is exacerbated by current standard treatments for BRVO. 
      These results may have implications for the timing and treatment type. 
      TRANSLATIONAL RELEVANCE: In the acute phase of BRVO, VEGF suppression with 
      bevacizumab and to a lesser extent with triamcinolone exacerbates apoptosis in 
      the inner retinal layers, which has implications for both the timing and choice 
      of treatment.
FAU - McAllister, Ian L
AU  - McAllister IL
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
AD  - Department of Ophthalmology, Royal Perth Hospital, Perth, Australia.
FAU - Vijayasekaran, Sarojini
AU  - Vijayasekaran S
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
FAU - Bhikoo, Riyaz
AU  - Bhikoo R
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
AD  - Department of Ophthalmology, Royal Perth Hospital, Perth, Australia.
FAU - Chen, Fred K
AU  - Chen FK
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
AD  - Department of Ophthalmology, Royal Perth Hospital, Perth, Australia.
AD  - Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, 
      Australia.
FAU - Zhang, Dan
AU  - Zhang D
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
FAU - Kanagalingam, Emily
AU  - Kanagalingam E
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
FAU - McLenachan, Samuel
AU  - McLenachan S
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
FAU - Yu, Dao-Yi
AU  - Yu DY
AD  - Centre for Ophthalmology and Visual Science, The University of Western Australia, 
      Perth, Australia.
AD  - Lions Eye Institute, The University of Western Australia, Perth, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
RN  - F446C597KA (Triamcinolone Acetonide)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Swine
MH  - Animals
MH  - *Triamcinolone Acetonide/pharmacology/therapeutic use
MH  - Bevacizumab/pharmacology/therapeutic use
MH  - *Retinal Vein Occlusion/drug therapy
MH  - Vascular Endothelial Growth Factor A
MH  - Retina/metabolism
PMC - PMC9919627
COIS- Disclosure: I.L. McAllister, None; S. Vijayasekaran, None; R. Bhikoo, None; F.K. 
      Chen, None; D. Zhang, None; E. Kanagalingam, None; S. McLenachan, None; D.-Y. Yu, 
      None
EDAT- 2023/02/09 06:00
MHDA- 2023/02/11 06:00
PMCR- 2023/02/08
CRDT- 2023/02/08 11:34
PHST- 2023/02/08 11:34 [entrez]
PHST- 2023/02/09 06:00 [pubmed]
PHST- 2023/02/11 06:00 [medline]
PHST- 2023/02/08 00:00 [pmc-release]
AID - 2785351 [pii]
AID - TVST-22-4912 [pii]
AID - 10.1167/tvst.12.2.11 [doi]
PST - ppublish
SO  - Transl Vis Sci Technol. 2023 Feb 1;12(2):11. doi: 10.1167/tvst.12.2.11.